Jazz Pharmaceuticals Plc Stock EBITDA

JAZZ Stock

USD 137.96 1.91 1.40%

Jazz Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Jazz Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Jazz Stock. The fundamental analysis module provides a way to measure Jazz Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jazz Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	EBITDA	716.6 M	487 M

EBITDA is likely to drop to about 487 M in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Jazz Pharmaceuticals PLC Company EBITDA Analysis

Jazz Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Jazz Pharmaceuticals EBITDA

716.63 M

Most of Jazz Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jazz Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Jazz EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Jazz Pharmaceuticals is extremely important. It helps to project a fair market value of Jazz Stock properly, considering its historical fundamentals such as EBITDA. Since Jazz Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Jazz Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Jazz Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.92	0.31	0.8	0.95	0.98	0.98	0.99	0.34	0.99	0.91	0.96	0.95	0.67	0.4	0.0	-0.9	0.91	0.7	0.97	-0.43	0.92	0.7	0.8	-0.53
Total Stockholder Equity	0.92		0.23	0.94	0.82	0.83	0.91	0.92	0.59	0.84	0.88	0.85	0.92	0.59	0.41	0.15	-0.68	0.89	0.57	0.81	-0.51	0.75	0.77	0.77	-0.47
Net Debt	0.31	0.23		0.15	0.46	0.28	0.24	0.36	-0.31	0.33	-0.04	0.52	0.28	-0.32	0.36	0.59	-0.43	0.43	-0.09	0.24	-0.05	0.34	0.17	-0.04	0.56
Retained Earnings	0.8	0.94	0.15		0.66	0.68	0.79	0.8	0.7	0.69	0.77	0.72	0.85	0.5	0.34	0.14	-0.51	0.79	0.49	0.66	-0.58	0.56	0.76	0.69	-0.42
Accounts Payable	0.95	0.82	0.46	0.66		0.95	0.94	0.95	0.14	0.96	0.81	0.95	0.92	0.61	0.45	0.05	-0.92	0.88	0.63	0.94	-0.29	0.93	0.68	0.7	-0.39
Long Term Debt	0.98	0.83	0.28	0.68	0.95		0.96	0.96	0.22	1.0	0.89	0.94	0.91	0.69	0.33	-0.12	-0.94	0.86	0.74	1.0	-0.4	0.94	0.63	0.78	-0.57
Net Receivables	0.98	0.91	0.24	0.79	0.94	0.96		0.97	0.39	0.97	0.95	0.9	0.94	0.74	0.46	-0.06	-0.85	0.9	0.76	0.96	-0.38	0.9	0.71	0.83	-0.57
Good Will	0.99	0.92	0.36	0.8	0.95	0.96	0.97		0.29	0.97	0.88	0.97	0.95	0.63	0.4	0.11	-0.9	0.92	0.71	0.95	-0.48	0.88	0.68	0.74	-0.48
Short Term Investments	0.34	0.59	-0.31	0.7	0.14	0.22	0.39	0.29		0.22	0.55	0.16	0.37	0.36	0.22	-0.14	0.06	0.35	0.19	0.23	-0.27	0.17	0.63	0.58	-0.42
Total Liab	0.99	0.84	0.33	0.69	0.96	1.0	0.97	0.97	0.22		0.88	0.96	0.92	0.68	0.38	-0.07	-0.95	0.88	0.73	0.99	-0.38	0.95	0.64	0.77	-0.53
Total Current Assets	0.91	0.88	-0.04	0.77	0.81	0.89	0.95	0.88	0.55	0.88		0.76	0.85	0.83	0.42	-0.21	-0.71	0.8	0.75	0.9	-0.33	0.84	0.68	0.89	-0.72
Intangible Assets	0.96	0.85	0.52	0.72	0.95	0.94	0.9	0.97	0.16	0.96	0.76		0.92	0.5	0.34	0.13	-0.94	0.89	0.6	0.92	-0.45	0.88	0.63	0.65	-0.35
Property Plant Equipment	0.95	0.92	0.28	0.85	0.92	0.91	0.94	0.95	0.37	0.92	0.85	0.92		0.63	0.31	-0.02	-0.83	0.88	0.62	0.91	-0.53	0.83	0.78	0.74	-0.51
Current Deferred Revenue	0.67	0.59	-0.32	0.5	0.61	0.69	0.74	0.63	0.36	0.68	0.83	0.5	0.63		0.46	-0.47	-0.59	0.5	0.8	0.74	-0.03	0.65	0.45	0.71	-0.79
Short Term Debt	0.4	0.41	0.36	0.34	0.45	0.33	0.46	0.4	0.22	0.38	0.42	0.34	0.31	0.46		0.17	-0.31	0.43	0.34	0.36	0.36	0.43	0.29	0.35	0.03
Common Stock	0.0	0.15	0.59	0.14	0.05	-0.12	-0.06	0.11	-0.14	-0.07	-0.21	0.13	-0.02	-0.47	0.17		0.05	0.18	-0.2	-0.18	-0.21	-0.16	-0.01	-0.28	0.6
Net Tangible Assets	-0.9	-0.68	-0.43	-0.51	-0.92	-0.94	-0.85	-0.9	0.06	-0.95	-0.71	-0.94	-0.83	-0.59	-0.31	0.05		-0.79	-0.7	-0.94	0.32	-0.9	-0.49	-0.6	0.4
Capital Surpluse	0.91	0.89	0.43	0.79	0.88	0.86	0.9	0.92	0.35	0.88	0.8	0.89	0.88	0.5	0.43	0.18	-0.79		0.57	0.84	-0.42	0.88	0.71	0.83	-0.23
Deferred Long Term Liab	0.7	0.57	-0.09	0.49	0.63	0.74	0.76	0.71	0.19	0.73	0.75	0.6	0.62	0.8	0.34	-0.2	-0.7	0.57		0.76	-0.28	0.62	0.39	0.58	-0.65
Long Term Debt Total	0.97	0.81	0.24	0.66	0.94	1.0	0.96	0.95	0.23	0.99	0.9	0.92	0.91	0.74	0.36	-0.18	-0.94	0.84	0.76		-0.35	0.95	0.62	0.79	-0.6
Short Long Term Debt	-0.43	-0.51	-0.05	-0.58	-0.29	-0.4	-0.38	-0.48	-0.27	-0.38	-0.33	-0.45	-0.53	-0.03	0.36	-0.21	0.32	-0.42	-0.28	-0.35		-0.17	-0.37	-0.23	0.26
Net Invested Capital	0.92	0.75	0.34	0.56	0.93	0.94	0.9	0.88	0.17	0.95	0.84	0.88	0.83	0.65	0.43	-0.16	-0.9	0.88	0.62	0.95	-0.17		0.59	0.84	-0.42
Long Term Investments	0.7	0.77	0.17	0.76	0.68	0.63	0.71	0.68	0.63	0.64	0.68	0.63	0.78	0.45	0.29	-0.01	-0.49	0.71	0.39	0.62	-0.37	0.59		0.66	-0.35
Net Working Capital	0.8	0.77	-0.04	0.69	0.7	0.78	0.83	0.74	0.58	0.77	0.89	0.65	0.74	0.71	0.35	-0.28	-0.6	0.83	0.58	0.79	-0.23	0.84	0.66		-0.52
Capital Stock	-0.53	-0.47	0.56	-0.42	-0.39	-0.57	-0.57	-0.48	-0.42	-0.53	-0.72	-0.35	-0.51	-0.79	0.03	0.6	0.4	-0.23	-0.65	-0.6	0.26	-0.42	-0.35	-0.52

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Jazz Pharmaceuticals

Ebitda Over Time

Jazz Ebitda

Ebitda

487.04 Million

At this time, Jazz Pharmaceuticals' EBITDA is fairly stable compared to the past year.

According to the company disclosure, Jazz Pharmaceuticals PLC reported earnings before interest,tax, depreciation and amortization of 716.63 M. This is 18.33% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 81.62% higher than that of the company.

Jazz EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jazz Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics of similar companies.

Jazz Pharmaceuticals is currently under evaluation in ebitda category among its peers.

Jazz Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Jazz Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Jazz Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Jazz Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Jazz Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Jazz Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Jazz Pharmaceuticals' value.

		Shares
Geode Capital Management, Llc	2024-12-31	1.1 M
Polaris Capital Management, Llc	2024-12-31	1.1 M
Swedbank Ab	2024-12-31	1 M
Renaissance Technologies Corp	2024-12-31	1 M
Vestal Point Capital Lp	2024-12-31	975 K
Fuller & Thaler Asset Management Inc	2024-12-31	939.4 K
Fmr Inc	2024-12-31	742.3 K
Thompson, Siegel & Walmsley Llc	2024-12-31	700.9 K
Morgan Stanley - Brokerage Accounts	2024-12-31	661 K
Vanguard Group Inc	2024-12-31	6 M
Blackrock Inc	2024-12-31	5.9 M

Jazz Fundamentals

	Return On Equity	0.14
	Return On Asset	0.046
	Profit Margin	0.14 %
	Operating Margin	0.21 %
	Current Valuation	11.55 B
	Shares Outstanding	60.73 M
	Shares Owned By Insiders	3.08 %
	Shares Owned By Institutions	99.79 %
	Number Of Shares Shorted	4.53 M
	Price To Earning	35.18 X
	Price To Book	2.05 X
	Price To Sales	2.06 X
	Revenue	4.07 B
	Gross Profit	3.76 B
	EBITDA	716.63 M
	Net Income	560.12 M
	Cash And Equivalents	899.36 M
	Cash Per Share	14.28 X
	Total Debt	69.94 M
	Debt To Equity	2.12 %
	Current Ratio	3.16 X
	Book Value Per Share	67.52 X
	Cash Flow From Operations	1.4 B
	Short Ratio	4.96 X
	Earnings Per Share	8.65 X
	Price To Earnings To Growth	0.43 X
	Target Price	193.58
	Number Of Employees	2.8 K
	Beta	0.44
	Market Capitalization	8.38 B
	Total Asset	12.01 B
	Retained Earnings	1.13 B
	Working Capital	3.59 B
	Current Asset	1.26 B
	Current Liabilities	226.64 M
	Net Asset	12.01 B

About Jazz Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Jazz Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
CRM	Salesforce
CRM	Salesforce

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC